PIK3CA is a frequently mutated gene in solid cancers, including head and neck, lung, breast, and gastrointestinal malignancies. Cancer cells often develop resistance to PI3K inhibitors through mutations in the PI3K pathway or activation of alternative signaling pathways, rendering these inhibitors ineffective over time.

Mekanistic Therapeutics is developing MTX-531, a first-in-class small molecule that functions as a dual inhibitor of PI3K and EGFR pathways. By inhibiting EGFR, MTX-531 mitigates the need to escalate PI3K dosages, potentially reducing toxicity and broadening the therapeutic index. This targeted approach aims to overcome resistance mechanisms in PIK3CA mutant cancers, enhancing therapeutic efficacy and yielding more durable anti-tumor results. MTX-531 is designed to potentiate the efficacy of established treatments and exhibits significant synergy with RAS pathway inhibitors, radiation therapy, and immunotherapy.

Dual inhibition of PI3K and EGFR signaling pathways

Circumvents hyperglycemia induction, enhancing the safety margin

Synergistic activity with RAS pathway inhibitors, radiation therapy, and immunotherapy

Applicable across multiple cancer indications, including head and neck, breast, lung, and gastrointestinal cancers

Complete regressions observed in multiple preclinical models

Selected for the NCI’s NExT program to accelerate clinical development

The primary target audience includes patients with PIK3CA and KRAS mutant cancers across various solid tumor types, as well as oncologists and researchers focused on overcoming resistance to PI3K inhibitors.